BioSpace News Archive

Exactech Announces Successful First Revision Knee Replacement Surgery With Truliant® Instrumentation

Orthopaedic surgeons will have a chance to experience the Truliant primary and revision systems through live mechanical demonstrations Nov. 2-5 at the American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting, Booth #908 in Dallas, Texas.

November 1, 2017
·
2 min read
Bio NC

CALQUENCE (Acalabrutinib) Approved for Previously-Treated Mantle Cell Lymphoma, Available for Order at Biologics, Inc.

CALQUENCE is a highly selective orally available potent inhibitor of Bruton’s tyrosine kinase (BTK).

November 1, 2017
·
4 min read
Business

Aduro Biotech Reports Third Quarter 2017 Financial Results

Net loss for the third quarter of 2017 was $24.5 million, or $0.33 per share.

November 1, 2017
·
9 min read
Genetown

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employees received, in the aggregate, options to purchase 32,250 shares of Sarepta’s common stock.

November 1, 2017
·
1 min read
Business

TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017

In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

November 1, 2017
·
1 min read
Business

Kura Oncology to Report Third Quarter 2017 Financial Results

Management will host a webcast and conference call at 4:30 p.m. EST/1:30 p.m. PST that day to discuss the financial results and provide a corporate update.

November 1, 2017
·
1 min read
BIOPHYTIS Completes a 7.5M Euro Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases

Since July 1st, the Company has raised a total amount of €21 M.

November 1, 2017
·
4 min read
Business

Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

The company will host a conference call at 4:30pm ET today.

November 1, 2017
·
14 min read
BioCapital

Integrated Biotherapeutics Partners With CARB-X the First Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus

Integrated BioTherapeutics announced today that is has been awarded up to $168,000, with the possibility of up to $8.3M more based on the achievement of milestones, to develop the first entirely toxoid-based multivalent vaccine for the prevention of MRSA.

November 1, 2017
·
3 min read
Veloxis Pharmaceuticals Grants Warrants Under Existing Warrant Program

Today, the Board of Directors of Veloxis The company has decided to issue and grant warrants to 43 employees of the Company under the existing Warrant Program.

November 1, 2017
·
2 min read